Lead sponsor
Guangdong Raynovent Biotech Co., Ltd
11 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.
11
Trials led
8
Active
2,282
Total enrollment
6
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 1
6
Phase 2
2
Phase 3
3
Trials by status
Not yet recruiting
3
Recruiting
3
Active, not recruiting
2
Completed
3
Trials led
TrialKey I/E criterionPhaseStatusEnrollment
Evaluation of RAY1225 in Adult Participants Who Have Obesity or Are OverweightBMI ≥28Ph 3Recruiting640
A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 DiabetesBMI ≥20Ph 3Not yet recruiting600
A Study of RAY1225 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise AloneBMI ≥20Ph 3Not yet recruiting350
A Study of RAY1225 at Different Injection Sites in Participants With Different Body SizesBMI ≥19Ph 1Completed48
Drug-durg Interaction of RAY1225 With Warfarin, Atorvastatin, Metformin and DigoxinBMI 20-35Ph 1Active, not recruiting32
A Mass Balance Study Of 14C-RAY1225 Injection In Healthy Chinese ParticipantsBMI 20-35Ph 1Not yet recruiting8